Related Experiment Video
Updated: Jun 26, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
An immunological panacea for cancer-related cachexia
Jingyu Xue1, Tianyi Lu1, Kailin Yang2
1Department of Obstetrics and Gynecology, Development and Related Diseases of Women and Children Key Laboratory of Sichuan Province and State Key Laboratory of Biotherapy, West China Second University Hospital, Sichuan University, and Collaborative Innovation Center, Chengdu, PR China.
None:
Cancer cachexia, responsible for up to 30% of cancer deaths, has transitioned conceptually from a mere nutritional deficit into a highly coordinated, multi-organ immunometabolic network that systematically dismantles host homeostasis. This review synthesizes the paradigm-shifting discoveries that position the immune system as the central conductor of tissue wasting. We delineate how redundant inflammatory cascades, neuro-immune circuits, and local cellular plasticity converge to drive muscle and adipose catabolism. Furthermore, we dissect the metabolic competition for nutrients between tumor cells and host immunity, which accelerates structural degradation. Finally, we highlight how single-cell multiomics, spatial transcriptomics, and artificial intelligence are redefining clinical stratification, shifting the therapeutic horizon toward individualized, multi-node immunometabolic interventions, thereby providing a theoretical framework for the management of cachectic wasting syndrome.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
